We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cardiorenal outcomes
MedXY News
EnglishTag

cardiorenal outcomes

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit
Cardiologycardiorenal outcomesdulaglutide

Tirzepatide vs Dulaglutide: New Post Hoc SURPASS-CVOT Data Point to Broader Cardiorenal Benefit

By MedXY|Jun 19, 2026

Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities